Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma

Abstract

We describe the architectural patterns of advanced ovarian/pelvic high-grade serous carcinomas that have been treated with upfront surgery, followed by adjuvant chemotherapy or neoadjuvant chemotherapy, followed by interval debulking to explore the association with the chemotherapeutic response. For 70 cases of advanced (i.e. stage III/IV) high-grade serous carcinomas (33 platinum resistant/intermediate, 37 platinum sensitive; 24 neoadjuvantly treated, 44 primary surgery), all tumor-containing histologic slides were reviewed by 1 of 3 pathologists. Histologic type was confirmed and the following features were assessed: major architectural pattern and the presence of any of 8 predefined minor architectural patterns (papillary, transitional cell carcinoma-like, micropapillary, microcystic, nested papillary, slit-like, glandular, solid). A semiquantitative assessment of psammoma bodies, histiocytic response, necrosis, nuclear atypia, and single-cell invasion was performed. Mitotic count was performed in 10 HPF and 1 HPF was counted for intraepithelial lymphocytes. The morphologic features were tested for an association with previous neoadjuvant chemotherapy and response to chemotherapy (resistant/intermediate versus chemotherapy-sensitive cases stratified by neoadjuvant chemotherapy), which was carried out using χ tests for categorical variables and analysis of variance for continuous data. Combinations of features were analyzed using unsupervised clustering (Wald). Although 8 of 18 features were significantly different when samples from neoadjuvantly treated patients were compared with those not previously treated, no individual histomorphologic feature or a combination of features was associated with response to chemotherapy. Further subtyping of high-grade serous carcinomas will likely need ancillary molecular markers that may have a greater potential to identify cases that will not respond to platinum-based chemotherapy.

Accelerating type‐specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high‐throughput tool for case review

“…However, this will undoubtedly be a tiny proportion of cases and in fact does not appear to be relevant to any of the so‐called mixed histology tumours in this cohort. Overall, this reinforces the assertion that SER displays impressive morphological heterogeneity, and is largely in keeping with current literature on differentiating histotypes, both morphologically and molecularly …”

Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype‐specific Lynch syndrome screening in ovarian carcinomas

“…Nine tumours were classified as endometrioid carcinoma with clear cell‐like areas (NAPSA absent, 7/9; ESR1 present, 7/9), and two as clear cell carcinoma with endometrioid‐like areas (both NAPSA present, ESR1 absent), and these were included in the numbers above. To the tumours in the AOVT study, we added high‐grade and low‐grade serous carcinomas from two local TMAs: high‐grade serous carcinomas (68 after removal of five duplicates that overlapped with AOVT), and low‐grade serous carcinomas …”

Molecular alterations in indolent, aggressive and recurrent ovarian low‐grade serous carcinoma

“…Clinical information was extracted from the electronic chart (ARIA Electronic Medical Record; Varian Medical Systems, Palo Alto, CA, USA). For comparison of copy number variations, 58 HGSCs from a previous study were included . Ethical approval was received from the Alberta Cancer Research Ethics Committee (#26115).…”